Common questions about Mycelex Troche (FAQ)
Q: What is the difference between a 'troche' and a regular pill?
A: A troche, often called a lozenge, is a specialized dosage form designed to dissolve slowly in the mouth, which allows the active medicine to work directly where the infection is located (local action). In contrast, a regular pill or tablet is generally swallowed immediately and is intended for systemic absorption, where the medicine enters the general bloodstream to affect the whole body.
Q: What is the typical time frame to see an effect from Mycelex Troche?
A: Official information does not typically state a precise time frame for when initial relief may be noticed. Studies indicate that drug concentrations effective against the fungus can persist in the saliva for up to three hours after the troche dissolves. The duration of therapy used in official studies is typically 14 days.
Q: How long does the action of Mycelex Troche last in the mouth?
A: Studies examining the local effects of the troche show that concentrations of the active ingredient sufficient to slow or stop the growth of the fungus persist in the saliva for up to three hours after one troche has fully dissolved. Official administration schedules are based on the need to maintain concentrations over a period of time.
Q: Are there common foods or drinks that should be avoided while using Mycelex Troche?
A: Official documentation includes a general cautionary note regarding the concurrent use of the medication with food, alcohol, or tobacco. However, regulatory sources typically do not provide a detailed list of specific foods or drinks. The official caution should be noted.
Q: Is it normal to feel a change in taste after using Mycelex Troche?
A: Official regulatory documents indicate that unpleasant mouth sensations, including taste alteration, are described as one of the most frequently reported effects associated with use.
Q: What potential interactions exist between Mycelex Troche and blood thinners?
A: The active ingredient is documented as inhibiting an enzyme known as CYP3A4, which is involved in breaking down many other medicines. Official documents describe that co-administration with drugs that use this enzyme pathway, which includes some blood thinners, may require evaluation due to the potential for interaction.
Q: What are some less common but reported side effects of Mycelex Troche?
A: In addition to common gastrointestinal and mouth effects, regulatory documents detail a documented risk of hypersensitivity reactions. The documented risk of hypersensitivity reactions includes symptoms officially described as rash, itching, swelling, or difficulty breathing.
Q: Is Mycelex Troche appropriate for elderly patients?
A: Regulatory documentation notes that initial clinical studies did not include a sufficient number of subjects aged 65 and over to definitively establish if their response differs from younger subjects. However, clinical experience to date has generally not identified differences in responses between these two groups.
Q: What does official research evidence say about the effectiveness of Mycelex Troche?
A: Official prescribing information describes the outcomes measured in clinical trials, such as clinical cure (resolution of symptoms) and mycologic cure (elimination of the fungus). Official regulatory documents often include a statement noting that the relationship between laboratory-measured susceptibility and the actual clinical cure rate has not always been definitively established.
Q: Is Mycelex Troche available over the counter in some places?
A: The troche formulation is typically available by prescription only in countries like the United States and Canada. The active ingredient, Clotrimazole, however, is available in other topical forms, such as creams for skin infections, that may be sold over-the-counter.
Q: Are there different strengths or formulations of Mycelex Troche?
A: The prescription oral troche is officially supplied as a 10 mg dosage of Clotrimazole. While the active ingredient itself is found in other strengths and forms (like creams or vaginal tablets), those are specifically for managing fungal infections in other areas of the body.
Q: Can Mycelex Troche cause dizziness or drowsiness?
A: Official side effect information does not list dizziness or drowsiness as common or expected effects. However, severe dizziness is sometimes mentioned in official documentation as a symptom that may be associated with a serious, albeit rare, hypersensitivity reaction.
Q: Does Mycelex Troche have a high risk of drug resistance developing?
A: Official drug labeling notes that laboratory studies have not shown the development of resistance when Candida albicans is repeatedly exposed to the active ingredient. Official information does acknowledge that, in laboratory settings, individual organism tolerance has been observed.
Q: Is there a risk of overdose with Mycelex Troche?
A: Official information recognizes that a risk of overdose exists. If an overdose is suspected, regulatory guidance is to contact emergency medical assistance or a poison control center.
Q: What information is available about the pediatric use of Mycelex Troche?
A: The medication is approved for local treatment in pediatric patients aged 3 years and older. Safety and effectiveness are specifically noted as not established in children below the age of 3 years, reflecting unestablished safety data in this age group.
Q: Is there a generic version of Mycelex Troche available?
A: Yes, the active ingredient clotrimazole, in the troche formulation, is available as a generic medicine. This is offered as an alternative to the original brand-name product.
Q: Why is it sometimes called a 'lozenge' instead of a 'troche'?
A: The terms 'troche' and 'lozenge' are synonyms that are used interchangeably in regulatory documents and medical literature. They both refer to the same specialized dosage form designed to be slowly dissolved in the mouth.
Q: What are the common reasons a doctor might prescribe Mycelex Troche?
A: It is officially prescribed for the local treatment of oropharyngeal candidiasis (oral thrush) and as a preventative measure (prophylaxis). The preventative use is typically for patients who are immunocompromised due to therapies like chemotherapy or radiotherapy and are at high risk of developing the infection.
Q: What does 'systemic absorption' mean in relation to Mycelex Troche?
A: 'Systemic absorption' is the process where the active ingredient enters the general bloodstream and circulates throughout the body. The troche is primarily designed for local action in the mouth, so systemic absorption is limited and considered secondary to the main therapeutic effect.
Q: Why is this medicine typically prescribed for a specific duration?
A: Therapy is generally prescribed for a specific, short duration, such as 14 consecutive days for treatment. Regulatory documents state that only limited data are available on the safety and effectiveness of the troche after prolonged administration, defining the need to limit therapy to short-term use.
Q: Is the active ingredient in Mycelex Troche also used to treat other parts of the body?
A: Yes, the active ingredient Clotrimazole is used in other formulations, such as creams, solutions, and vaginal tablets. These different forms are used to treat fungal infections on the skin and in other localized areas of the body, but they are not the same as the oral troche.
Q: Are the safety facts for Mycelex Troche consistent across major regulatory bodies?
A: The core safety information, which includes contraindications (like hypersensitivity) and key warnings (such as the need for liver function monitoring in certain patients), is generally consistent across major international regulatory bodies, including those in the US, Europe, and Canada.
